The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer-Reference-Cited by-同舟云学术

The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer

Published:2008-12 Issue:11 Volume:102 Page:1531-1538
ISSN:1464-4096
Container-title:BJU International
language:en
Short-container-title:

Author:

Klotz Laurence,Boccon-Gibod Laurent,Shore Neal D.,Andreou Cal,Persson Bo-Eric,Cantor Per,Jensen Jens-Kristian,Olesen Tine Kold,Schröder Fritz H.

Publisher

Wiley

Subject

Urology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1464-410X.2008.08183.x/fullpdf

Reference26 articles.

1. Clinical Review 37 Endocrine treatment of prostate cancer;Santen;J Clin Endocrinol Metab,1992

2. Gonadotrophin-releasing hormone and its analogues;Conn;N Engl J Med,1991

3. Comparison of single-agent androgen suppression for advanced prostate cancer;Lepor;Rev Urol,2005

4. Importance of early tumour exacerbation in patients treated with long acting analogues of gonadotrophin releasing hormone for advanced prostatic cancer;Waxman;BMJ,1985

5. Sudden death due to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate;Thompson;J Urol,1990

Cited by 479 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. GnRH antagonist monotherapy versus a GnRH agonist plus bicalutamide for advanced hormone‐sensitive prostate cancer; KYUCOG‐1401;International Journal of Urology;2023-12-26

2. Prognostic significance of nadir PSA value and time to nadir PSA in patients with metastatic castration-naive prostate cancer receiving first-line hormonotherapy;Journal of Cancer Research and Therapeutics;2023-12-15

3. Follicle-Stimulating Hormone Exacerbates Cardiovascular Disease in the Presence of Low or Castrate Testosterone Levels;JACC: Basic to Translational Science;2023-12

4. Testosterone Recovery for Relugolix Versus Leuprolide in Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study;European Urology Oncology;2023-12

5. A Critical Analysis of the FDA’s Omics-Driven Pharmacodynamic Biomarkers to Establish Biosimilarity;Pharmaceuticals;2023-11-02